Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab
Sponsor: Zeneus Pharma